2022
An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntipsychotic AgentsAnxiety DisordersBenzodiazepinesHumansQuetiapine FumarateSelective Serotonin Reuptake InhibitorsSystematic Reviews as TopicConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorder
2021
Commentary: Diagnostic and Treatment Issues in Psychosis
Garakani A. Commentary: Diagnostic and Treatment Issues in Psychosis. Journal Of Psychiatric Practice 2021, 27: 338-339. PMID: 34398586, DOI: 10.1097/pra.0000000000000562.Commentaries, Editorials and LettersMeSH KeywordsAntipsychotic AgentsFemaleHumansPsychotic DisordersSchizophreniaSelf-Injurious BehaviorViolenceConceptsPsychotic symptomsUse of intranasalWide differential diagnosisFirst-episode schizophreniaMore common conditionsRare presentationPostpartum periodDifferential diagnosisPsychotic episodeCommon conditionSymptomsTreatment issuesPeriodic catatoniaPatientsFirst caseThird caseDiagnosisTreatmentBroad spectrumCommentary: Diagnostic Challenges in Evaluating Adolescents
Garakani A. Commentary: Diagnostic Challenges in Evaluating Adolescents. Journal Of Psychiatric Practice 2021, 27: 239-240. PMID: 33939380, DOI: 10.1097/pra.0000000000000553.Commentaries, Editorials and LettersMeSH KeywordsAdolescentAdultAntipsychotic AgentsDelusionsFemaleHallucinationsHumansPsychotic DisordersSchizophreniaConceptsDiagnostic challengeConstellation of symptomsProminent mood symptomsPosttraumatic stress disorderFemale patientsTrauma-related symptomsMedication treatmentAntipsychotic medicationAdolescent patientsUnnecessary treatmentVisual hallucinationsDifferential diagnosisPatient reportsTerms of stigmaMood symptomsDepressive symptomsPsychotic symptomsSide effectsPatientsPsychotic disordersSuicidal ideasFull differential diagnosisAuditory hallucinationsCotard's syndromeIncorrect diagnosis
2020
Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm.
Garakani A, Buono FD, Marotta RF. Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm. Journal Of Clinical Psychopharmacology 2020, 40: 507-509. PMID: 32701906, DOI: 10.1097/jcp.0000000000001248.Peer-Reviewed Case Reports and Technical NotesThe effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series.
Marotta RF, Buono FD, Garakani A, Collins E, Cerrito B, David Rowe DR. The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series. Annals Of Clinical Psychiatry 2020, 32: 90-96. PMID: 32343282.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdultAntipsychotic AgentsBrief Psychiatric Rating ScaleClozapineFemaleHumansMaleOff-Label UseOxytocinRetrospective StudiesSchizophreniaYoung AdultConceptsTreatment-resistant schizophreniaNegative symptomsAtypical antipsychoticsRetrospective chart reviewInitial case seriesAugmentation of clozapineChronic psychotic illnessNegative Syndrome ScaleYoung adult inpatientsSymptoms of schizophreniaParent/guardian reportsChart reviewCase seriesAdult inpatientsProspective studyAntipsychotic medicationClinical reviewTherapeutic responsePsychotic illnessTreatment approachesSyndrome ScalePositive symptomsTreating psychiatristSymptomsSustained treatment
2010
The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances
Hirschowitz J, Kolevzon A, Garakani A. The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances. Harvard Review Of Psychiatry 2010, 18: 266-278. PMID: 20825264, DOI: 10.3109/10673229.2010.507042.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntidepressive AgentsAntimanic AgentsAntipsychotic AgentsBipolar DisorderHumansLithium CompoundsConceptsBipolar disorderGold standardMajor treatment guidelinesFirst-line treatmentMainstay of treatmentUse of lamotrigineTreatment of maniaBipolar maintenanceAtypical antipsychoticsTreatment guidelinesBipolar depressionMaintenance treatmentPharmacological treatmentFDA indicationMEDLINE searchNew agentsPotential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2008
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology 2008, 23: 269-275. PMID: 18703936, DOI: 10.1097/yic.0b013e328301a74c.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating Scale scoreMajor depressive disorderDepression Rating Scale scoresHamilton Anxiety ScaleRating Scale scoresPlacebo groupDepressive disorderScale scoreCGI improvement scoreCombination of quetiapinePlacebo-controlled trialClinical global improvementWeeks of treatmentOnset of actionMixed effects linear regressionQuetiapine augmentationAnxiety ScaleFluoxetine groupFluoxetine treatmentCGI scoresImproved sleepMixed effects regressionInsomnia scoresQuetiapineFluoxetine